'BSY’s hands tied down by the Central leaders'

Bengaluru, May 19: Containment zones in Karnataka will be much smaller in size under the latest lockdown norms. However, rules and loopholes will be tightened and action against violators will be stringent in order to check the spread of the disease.

Revised guidelines issued by the Centre to the state, reveal containment zones are delineated based on mapping of cases and contacts. Intensive action will be carried out in these areas with the aim of breaking the chain of transmission. Therefore, the area of a containment zone should be appropriately defined by the district administration/local urban bodies with technical inputs at local level.

The health department is considering shrinking the size of containment zones from the existing 100 metres to open up more space for economic activities. Medical education minister K Sudhakar, also a member of the Covid taskforce, said additional chief secretary (health department) Javed Akthar will issue a new definition of a containment zone after the Covid-19 taskforce holds its next meeting.

“We are planning to further shrink it and restrict containment zones to an apartment complex, independent house or even a lane where the Covid-19 patient resides,” Sudhakar said. He went on to say bigger containment zones will impede businesses and normal activities in the vicinity, something which the government wants to avoid.

The minister said Karnataka will also do away with colour-coding districts. “With restrictions being relaxed for almost all activities, it does not make sense to pursue with colour codes. It is either containment zone or outside containment zone,” he said.

In rural areas, the minister said containment zones will be identified by the taluk heads. Government sources say it is difficult to restrict activities to certain areas or smaller location in rural areas as farmers and people will have to travel to the outskirts of their villages for their livelihood.

An official said, a containment operation (large outbreak or cluster) is deemed successful when no case is reported in 28 days from the containment zone.

New Delhi, Jun 11: The Department of Pharmaceuticals has given its nod for lifting of ban on the export of hydroxychloroquine, Union Minister D V Sadananda Gowda said on Wednesday.

India had banned export of hydroxychloroquine on March 25, with some exceptions, amid views in some quarters that the drug could be used to fight COVID-19. On April 4, it completely banned the exports without any exception.

"Department of Pharmaceuticals has approved the lifting of ban on export of Hydroxychloroquine API as well as formulations. Manufacturers except SEZ/EOU Units have to supply 20 per cent production in the domestic market," the minister of chemicals and fertilisers said in a tweet.

The Directorate General of Foreign Trade (DGFT) has been asked to issue formal notification in this regard, he added.

In another tweet, Gowda said he held discussions with representatives of pharma companies along with some of his ministerial colleagues on the challenges being faced by the industry and on the roadmap to boost exports.

"Had detailed discussion with representatives of pharma companies & association, stakeholder Ministries along with Hon Ministers @piyushGoyal  ji, @HardeepSPuri  ji, & @MansukhMandviya  ji on entire gamut of challenges faced by the industry as well as strategies to boost pharma export," Gowda tweeted.

India exported hydroxychloroquine API (active pharmaceutical ingredient) worth USD 1.22 billion in April-January 2019-20.

During the same period, exports of formulations made from hydroxychloroquine was at USD 5.50 billion.

Bengaluru, Mar 11: The Insurance Regulatory Authority of India has asked insurers to settle all claims related to coronavirus expeditiously under existing health policies that provide for treatment of hospitalisation expenses.

It has also asked insurers to design products covering the cost of treatment of coronavirus that has fast spread across the world and also resulted in increasing number of infections in India. There has been over 3,000 deaths globally and 58 cases tested positive in India.

In order to provide need-based health insurance coverage, insurers are intro ducing products for various specific diseases, including vector borne diseases. "For the purpose of meeting health insurance requirements of various sections, insurers are advised to design products covering the costs of treatment for coronavirus," the IRDAI said in a circular.

The regulator said that under existing health insurance policies where hospitalisation is covered, not only the cases related to coronvirus disease (COVID-19) shall be expeditiously handled, but all the costs of admissible medic al expenses during the course of treatment, including the treatment during quarantine period, should be settled in accordance to the applicable terms and conditions of policy contract and the extant regulatory framework.

This would bring much needed relief to policy holders some of whom were facing difficulty in getting coverage for treatment takers to coronavirus. In the absence of clear information, a few hospitals were reportedly denying for forward such claims of policy holders to the insurers.

IRDAI has now said that all the claims reported under COVID-19 shall be thoro ughly reviewed by review committee before repudiating the claims. This would prevent blanket rejection of such claims.

But to get full claim for treatment of coronavirus, industry experts said, a person should be hospitalised at least for 24 hours. Most insurers do not c over outpatient treatment.